Drug
Symtuza
Symtuza is a pharmaceutical drug with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_4
3
60%
Ph phase_3
2
40%
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Phase Distribution5 total trials
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
3(60.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (40.0%)
Phase 43 (60.0%)
Trials by Status
terminated120%
unknown240%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
The Late Presenter Treatment Optimisation Study
NCT03696160
terminatedphase_4
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
NCT04240210
completedphase_3
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
NCT04653194
unknownphase_4
Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain
NCT05463783
unknownphase_4
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
NCT04225325
Clinical Trials (5)
Showing 5 of 5 trials
NCT03696160Phase 3
The Late Presenter Treatment Optimisation Study
NCT04240210Phase 4
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
NCT04653194Phase 3
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
NCT05463783Phase 4
Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain
NCT04225325Phase 4
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5